Cookie Settings

We use cookies to optimize our website. These include cookies that are necessary for the operation of the site, as well as those that are only used for anonymous statistic. You can decide for yourself which categories you want to allow. Further information can be found in our data privacy protection .


These cookies are necessary to run the core functionalities of this website and cannot be disabled.

Name Webedition CMS
Purpose This cookie is required by the CMS (Content Management System) Webedition for the system to function correctly. Typically, this cookie is deleted when the browser is closed.
Name econda
Purpose Session cookie emos_jcsid for the web analysis software econda. This runs in the “anonymized measurement” mode. There is no personal reference. As soon as the user leaves the site, tracking is ended and all data in the browser are automatically deleted.

These cookies help us understand how visitors interact with our website by collecting and analyzing information anonymously. Depending on the tool, one or more cookies are set by the provider.

Name econda
Purpose Statistics
External media

Content from external media platforms is blocked by default. If cookies from external media are accepted, access to this content no longer requires manual consent.

Name YouTube
Purpose Show YouTube content
Name Twitter
Purpose activate Twitter Feeds

Programmable gene scissors revolutionize life sciences

Meyenburg Prize 2016 goes to Emmanuelle Charpentier

No. 53 | 20/12/2016 | by Koh

The Meyenburg Prize 2016 endowed with 50,000 Euros goes to the microbiologist Emmanuelle Charpentier from the Max Planck Institute for Infection Biology in Berlin. She receives the award for her breakthrough work in developing programmable "gene scissors". This new technology that makes genetic manipulation fast and simple. The Meyenburg Prize will be presented during a symposium at the German Cancer Research Center on Tuesday, 20 December 2016.

Emmanuelle Charpentier

Emmanuelle Charpentier was the first who understood that the molecular scissors CRISPR-Cas9 from the bacterium Streptococcus pyogenes can be exploited as a tool for genome silencing and engineering. Her research group showed that the combination of two RNAs, which they later combined into along with the protein Cas9 were both necessary and sufficient for the gene editing process. This tool can now be programmed to actually find and cut target sequences of any DNA strand. Together with Jennifer Doudna of the University of California in Berkeley, Charpentier has thus discovered precision tool for making changes to the genome.

"It is the special achievement of Emmanuelle Charpentier to have recognized this potential and to demonstrate its far-reaching applications. The seminal article in Science with Emmanuelle Charpentier as senior author was published only four years ago, but the CRISPR-Cas9 technology has quickly become one of the most sought-after tools in molecular biology research," says Christof von Kalle, member of the board of the Meyenburg Foundation. "Charpentier's discovery is similarly significant to the life sciences as the techniques of sequencing or PCR."

Compared to the methods of sequence-specific cutting of the DNA already known, CRISPR-Cas9 is easy and fast to use, so the method has rapidly been adopted in all life science laboratories. Thus the extremely elaborate process of altering the genome has become a routine procedure.

The application possibilities are enormous: With CRISPR-Cas9 scientists can switch genes on and off, and change or replace them. Basic researchers use the technique to investigate how individual genetic changes affect the emergence of diseases or the development of an organism. Researchers have already devised ways of using CRISPR-Cas9 to eradicate disease-transmitting mosquitoes, or to provide agricultural crops with special properties. In mice, various disease-inducing gene mutations have already been corrected with CRISPR technology. In initial clinical trials currently underway in China and the US, doctors are investigating whether immune cells altered with the help of CRISPR-Cas9 can prove to be effective in cancer therapy.

CRISPR-Cas9 is part of the defense system of bacteria, needed to fight virus infections. To do so, bacteria incorporate short pieces of viral DNA into their genome, virtually as a molecular fingerprint of the enemy. When re-infected with the same virus, the bacterium identifies the intruder by means of the stored fingerprint and cuts the virus gene at exactly this point.

In 2011, Emmanuelle Charpentier already described the two components of the CRISPR-Cas9 system in the Streptococcus pyogenes bacterium, and showed that the system works like a precision scalpel. The molecular scissors are programmed and directed by an RNA molecule. Charpentier's and her collaborating researchers' achievements also include to making the scissors simpler and more user-friendly.

Emmanuelle Charpentier (48) studied microbiology, genetics and biochemistry in Paris and obtained a doctorate at the Pasteur institute there. After positions in New York and Memphis, Charpentier joined the University of Vienna in 2002 and moved from there in 2009, to the University of Umeå, Sweden, where she is still visiting professor.

Charpentier came to Germany in 2013 as part of a Humboldt professorship. She initially headed a research department at the Helmholtz Center for Infection Research in Braunschweig and was a professor at Hannover Medical School. Since October 2015, she has been director at the Max Planck Institute for Infection Biology in Berlin. Charpentier has been awarded with more than two dozen awards. She received, among other prizes, the Breakthrough Prize in Life Sciences, endowed with three million dollars, and the Leibniz Prize of the German Research Foundation. In 2013, she co-founded the company CRISPR Therapeutics, and in 2014 the company ERS Genomics.

The Meyenburg Foundation under the umbrella of the German Cancer Research Center has been granting the award since 1981. Dr. Marion Meyenburg, daughter of the sponsors Wilhelm and Maria Meyenburg, will personally present this year's prize at the end of the symposium. The award, which is granted every year for outstanding achievements in the field of cancer research, is one of the most highly endowed science awards in Germany. The importance of this award is also reflected by the fact that numerous Meyenburg award winners have also been awarded the Nobel Prize: Andrew Fire, Meyenburg Prize winner 2002, received the Nobel Prize in Medicine in 2006. In 2009, Elizabeth Blackburn, winner of the 2006 Meyenburg Prize, received the Nobel Prize for Medicine. Shinya Yamanaka, Meyenburg Prize winner in 2007, won the Nobel Prize for Medicine in 2012, and Stefan Hell, Meyenburg Prize winner in 2011, received the Nobel Prize for Chemistry 2014.

The Meyenburg Symposium will begin on 20 December 2016 at 3:30pm in the lecture hall at the German Cancer Research Center. Speakers beside Emmanuelle Charpentier, will be the molecular biologists Michael Boutros from the DKFZ and Zoltan Ivics from the Paul Ehrlich Institute in Langen near Frankfurt. A lecture by the prominent bee researcher Jürgen Tautz from the University of Würzburg, who talks about the fascinating world of honeybees, promises a change from molecular biology.

How the gene scissors CRISPR-Cas9 work is also explained in the Helmholtz comic "Klar soweit?".

With more than 3,000 employees, the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) is Germany’s largest biomedical research institute. DKFZ scientists identify cancer risk factors, investigate how cancer progresses and develop new cancer prevention strategies. They are also developing new methods to diagnose tumors more precisely and treat cancer patients more successfully. The DKFZ's Cancer Information Service (KID) provides patients, interested citizens and experts with individual answers to questions relating to cancer.

To transfer promising approaches from cancer research to the clinic and thus improve the prognosis of cancer patients, the DKFZ cooperates with excellent research institutions and university hospitals throughout Germany:

  • National Center for Tumor Diseases (NCT, 6 sites)
  • German Cancer Consortium (DKTK, 8 sites)
  • Hopp Children's Cancer Center (KiTZ) Heidelberg
  • Helmholtz Institute for Translational Oncology (HI-TRON Mainz) - A Helmholtz Institute of the DKFZ
  • DKFZ-Hector Cancer Institute at the University Medical Center Mannheim
  • National Cancer Prevention Center (jointly with German Cancer Aid)
The DKFZ is 90 percent financed by the Federal Ministry of Education and Research and 10 percent by the state of Baden-Württemberg. The DKFZ is a member of the Helmholtz Association of German Research Centers.


Subscribe to our RSS-Feed.

to top
powered by webEdition CMS